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Clear cell papillary renal cell carcinoma (CCPRCC) is a
recently recognised neoplasm with a broad spectrum of
morphological characteristics, thus representing a chal-
lenging differential diagnosis, especially with the low ma-
lignant potential multicystic renal cell neoplasms and clear
cell renal cell carcinoma. We selected 14 cases of
CCPRCC with a wide spectrum of morphological features
diagnosed on morphology and CK7 immunoreactivity and
analysed them using a panel of immunohistochemical
markers, focusing on 34bE12 and related CKs 1,5,10 and
14 and several molecular analyses such as fluorescence
in situ hybridisation (FISH), array comparative genomic
hybridisation (aCGH), VHL methylation, VHL and TCEB1
sequencing and multiplex ligation-dependent probe
amplification (MLPA). Twelve of 13 (92%) CCPRCC tu-
mours were positive for 34bE12. One tumour without 3p
alteration by FISH revealed VHL mutation and 3p deletion
at aCGH; thus, it was re-classified as clear cell RCC. We
concluded that: (1) immunohistochemical expression of
CK7 is necessary for diagnostic purposes, but may not be
sufficient to identify CCPRCC, while 34bE12, in part due to
the presence of CK14 antigen expression, can be
extremely useful for the recognition of this tumour; and (2)
further molecular analysis of chromosome 3p should be
considered to support of CCPRCC diagnosis, when FISH
analysis does not evidence the common loss of chromo-
some 3p.
Key words: Clear cell papillary renal cell carcinoma; CK7 immunoreactivity;
34bE12; CK14 antigen expression; FISH analysis; VHL mutation; chromo-
some 3p deletion; aCGH; biomarker.
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Clear cell papillary renal cell carcinoma (CCPRCC) is a
recently recognised neoplasm that occurs in patients with
end-stage renal disease and acquired cystic kidney disease as
well as in otherwise normal kidneys.1,2 It is estimated that
these tumours constitute up to 3% of adult renal cell carci-
nomas (RCCs)3 and are the fourth most common histological
type of RCC.4 These tumours were originally described as
being multicystic, with a prominent papillary architecture.
Initial reports indicated that these tumours were composed
entirely of clear cells with nuclei usually arranged in a linear
fashion away from the basement membrane having a su-
perficial resemblance to the cells of early secretory endo-
metrium.1 Moreover, the neoplastic cells were initially
reported to constantly and diffusely express cytokeratin (CK)
7 and to be predominantly negative for alpha-methylacyl-
CoA racemase (P504S) and CD10. A characteristic genetic
alteration has not yet been identified for CCPRCC;2,5–8
however, the majority of tumours do not show the gains of
chromosome 7 and 172,3,5,7 characteristic of papillary RCC.8
They similarly lack chromosome 3p deletion and mutation or
methylation of the VHL gene, which characterises clear cell
RCC. Rohan et al. reported a series of nine tumours showing
co-expression of CAIX, HIF-1alpha, and GLUT-1 in the
absence of VHL gene alterations, which suggests activation
of the HIF pathway by non-VHL-dependent mechanisms.5 In
this study the authors concluded that these tumours were
easily separable from papillary RCC with clear cell changes
and clear cell RCC with focal papillary architecture, based on
morphological features. Moreover, they noted that in only
rare instances was the support of immunohistochemical
staining an absolute requirement for differentiating between
these two tumour types.5 Williamson et al. have highlighted
examples of CCPRCC in which the papillary component is
relatively inconspicuous, with predominance of a cystic or
prominent solid or dense tubular component. They alsoier B.V. on behalf of Royal College of Pathologists of Australasia.
34bE12 FOR CLEAR CELL PAPILLARY RENAL CARCINOMA 11showed 59% of these tumours to express CD10, especially in
the cystic areas and thus to some degree mimic both low
malignant potential multicystic renal cell neoplasms and
conventional clear cell RCC.9 In addition to these findings,
CCPRCC-like tumours have been reported in patients with or
without Von Hippel–Lindau disease, underlining the diffi-
culties in distinguishing CCPRCC from conventional clear
cell RCC.10,11 More recently, Aron et al. and Deml et al.
have reported a few cases of CCPRCC notably with VHL
mutation12,13 and Hakimi et al. observed TCEB1 mutation in
a series of tumours with morphological and immunohisto-
chemical overlap with CCPRCC.14 In this study we
performed a thorough immunophenotypical analysis of a
total of 14 CCPRCC cases, paying special attention to the
expression of 34bE12 and CK14. We also evaluated the
expression of these markers in a set of tissue microarrays
(TMAs) containing 150 cases of conventional clear cell
RCCs. Moreover, we undertook a detailed genetic analysis of
a subset of five cases with microscopic features representa-




A total of 14 cases of CCPRCC were accessioned from the archives of the
Department of Pathology and Diagnostics, University and Hospital Trust of
Verona and Anatomic Pathology, Pederzoli Hospital of Peschiera del Garda,
Verona (diagnosed from 2003 to 2012). In these cases the diagnosis was
based on the presence of specific morphological features previously described
in these tumours, including papillary, branching tubular, tubulo-glandular and
cystic patterns. For each case, 1–12 (on average 5) paraffin-embedded tissue
blocks were available. Sections 3 mm thick were cut from tissue blocks and
stained with haematoxylin and eosin (H&E). The diagnosis was reviewed
independently by three urological pathologists (MB, SG, GM). TMAs
containing 150 cases of clear cell RCC were also used for immunostain
evaluation as comparison with CCPRCC.
Immunohistochemical analysis
The immunohistochemical profile of each tumour was investigated using a
panel of antibodies that consisted of: CD10 (clone 56C6, 1:10 dilution;
Novocastra, USA); cytokeratin 7 (clone OV-TL 12/30, 1:400 dilution; Bio-
genex, USA); cytokeratin 34bE12 (clone 34bE12, 1:40 dilution; Dako,
USA); cytokeratin 1 (clone 34bB4, 1:50 dilution; Novocastra); cytokeratin 5
(clone XM26, 1:100 dilution; Novocastra); cytokeratin 10 (clone 2HP1, 1:50
dilution; Novocastra); cytokeratin 14 (clone LL002, 1:50 dilution; Biogenex);
cytokeratin AE1/AE3 (clone AE1/AE3, 1:100; Dako); parvalbumin (clone
P19, 1:400 dilution; Sigma Chemical Company, USA); CAIX (polyclonal,
1:100 dilution; Abcam, UK); SLC2A1 (GLUT1; polyclonal, rabbit, 1:100
dilution; Dako); alpha-methylacyl-CoA racemase (P504S; clone 13H7, 1:50
dilution; Dako); S100A1 (clone M01, 1:800 dilution; Abnova, Taiwan);
desmin (clone D33, 1:500 dilution; Dako); a-smooth muscle actin (clone
1A4, 1:250 dilution; Dako); oestrogen receptor (1:20 dilution; Dako), pro-
gesterone receptor (clone PgR 636, 1:20 dilution; Dako); HMB45 (clone
HMB45, 1:300 dilution; Dako) and cathepsin K (clone 3F9, 1:2000 dilution;
Abcam). Immunoreactions were developed using a non-biotin, highly sensi-
tive system (Envision peroxidase detection system; Dako) designed to prevent
possible false-positive staining resulting from endogenous biotin present in
the tissue.
Protein extraction and western blot analysis
Proteins were extracted from neoplastic tissues of six CCPRCCs and 10 clear
cell RCCs. For each sample 20 serial 10 mm sections were collected into an
Eppendorf tube, and 150 mL Cell Lysis Buffer (Cell Signaling Technology,
USA) was added prior to heating at 100C for 5 min. Samples were cooled for
5 min on ice, centrifuged at 140,000 × g for 15 min and supernatants were
transferred to a new collection tube and stored at –20C. Proteinquantification was performed using the Bio-Rad protein assay kit (Bio-Rad,
USA) according to the manufacturer’s instructions. Twenty-five mg of
extracted lysates was resolved in 10% polyacrylamide SDS-PAGE gel in a
BioRad Mini Protean tetra cell system at 150V for 1 h. Electrophoresed
proteins were transferred into a nitrocellulose membrane at 250 mA for
90 min. The membranes were blocked in TBST (Tris-Buffered saline and
Tween 20) plus 5% non-fat dry milk for 1h at RT with constant shaking.
Subsequently, the blots were incubated overnight, washed three times with
TBST and incubated with the specific secondary anti-mouse or anti-rabbit
peroxidase-conjugated anti-IgG antibody (diluted 1:2000; Cell Signaling,
USA). After three washes with TBST, the immunoblots were visualised with
ECLplus Western Blotting Substrate (Amersham/GE Healthcare Europe,
Germany). Expression levels of each marker were quantified with ImageJ
(https://imagej.nih.gov/ij/index.html) densitometric analysis.
Array comparative genomic hybridisation (aCGH) and data analysis
Microdissection of formalin fixed, paraffin embedded (FFPE) kidney tumours
was performed.
Genomic DNA was isolated using a QIAamp DNA mini kit (Qiagen
Nordic, Finland) and quantified on the NanoDrop spectrophotometer
(NanoDrop Technologies, USA). As a reference we used DNA from pooled
peripheral blood leukocytes of normal males. We screened for copy number
alterations in five tumours using the Agilent Human 244K array format
containing ~240,000 oligonucleotide probes, covering both coding and non-
coding genome regions (Agilent Technologies, USA). Briefly, 1.5 mg of
tumour and reference DNA were digested, labelled and hybridised according
to the Agilent protocols. The array images obtained after scanning (Agilent
scanner G2565BA) were processed with Feature Extraction software (version
10.5), and the output data files were analysed with the Agilent Genomic
Workbench. To identify copy number alterations we used the aberration
detection method 2 (ADM-2) algorithm. To exclude small variances in the
data we set up a custom aberration filter identifying alterations in copy
number if a minimum of eight probes gained or lost were identified, with a
minimum absolute average log ratio for the region being 0.5. Regions with
small copy number variations were excluded by comparing and visualising
the copy number variant regions of the Genomic Workbench software tool.
Fluorescence in situ hybridisation (FISH)
FISH analysis was performed using a centromeric-specific probe for the
chromosome 3 centromere (SpectrumGreen CEP3; Abbott, Italy) and a
subtelomeric probe for 3p25 (SpectrumGreen 3p-LSI; Abbott) in order to
evaluate 3p deletion. Centromeric-specific probes for the chromosome 7 and
17 centromere were also used (SpectrumGreen, SpectrumOrange; Abbott).
From the whole-tissue sections, 3 mm sections were cut from paraffin-
embedded blocks. The paraffin was removed from the sections with two
10 min washes with xylene. After hydrating in 100%, 85%, and 70% ethanol
solutions (10 min), rinsing in distilled water (10 min), and twice in phosphate-
buffered solution (pH 7, 10 min each), the slides were fixed in methanol-acetic
acid 3:1 for 10 min and air-dried. Next, the sections were treated in a 2X
standard saline citrate solution for 15 min at 37C, dehydrated in consecutive
70%, 85%, and 100% ethanol solution for 1 min each and then dried. Next,
the sections were bathed in 0.1 mM citric acid (pH 6) solution at 85C for 1 h.
They were then dehydrated in a series of ethanol solutions and dried. The
tissue was digested by applying 0.75 mL of pepsin (Sigma, USA) solution
(4 mg/mL in 0.9% NaCl, pH 1.5) to each slide and incubating in a humidified
box for 30 min at 37C. Next, the slides were rinsed with distilled water for a
few seconds, dehydrated in graded ethanol solutions, and dried. Centromeric
probes for chromosomes 3 and the locus specific sub-telomeric probe 3p were
used. Each probe was diluted 1:20 in t-DenHyb-2 buffer (LiStar-FISH,
Italy).15,16 Ten mL of diluted probe was applied to each slide and cover slips
were placed over the slides. Denaturation was achieved by incubating the
slides at 80C for 10 min in a humidified box, and then hybridisation was
carried out at 37C for 16 h. The cover slips were later removed and the slides
were immersed at room temperature in 0.5X SSC for 2 min, in 50% form-
amide/1X SSC for 5 min, and in 2X SSC for 2 min. The slides were air-dried
and counterstained with 10 mL DAPI/Antifade (DAPI in Fluorguard, 0.5 mg/
ml; Insitus, USA). The slides were examined using an Olympus BIX-61
microscope (Olympus, Germany) with filters for SpectrumGreen, and the
UV Filter for the DAPI nuclear counterstain. The signals were recorded with a
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as reported previously.2,16,17 Signals from 100–200 nuclei were counted,
focusing only on neoplastic nuclei from the epithelial components. The
control distribution of signals was assessed on non-neoplastic renal paren-
chyma adjacent to the tumours. The value of the ratio (3p/3) on the normal
renal parenchyma + 3SD set to 1.03 + 3SD 0.05 = 1.19 + 3SD was used per
each fluorescent score number. The percentage of neoplastic nuclei showing
one, two or more than two fluorescent signals were respectively recorded as
having monosomic, disomic or gains of chromosomes. Normal adjacent tissue
was used as control.
VHL sequencing analysis
Five 10 mm thick sections of tumour tissue were cut from FFPE blocks. DNA
was extracted. Polymerase chain reaction (PCR) for VHL gene analysis was
performed using primer sequences as reported.18,19 Normal tissues from the
same patients were used as a reference. The reaction conditions were as
follows: 12.5 mL of HotStart Taq PCR Master Mix (Qiagen, Germany),
10 pmol of each primer, 100 ng of template DNA, and distilled water up to
25 mL. Amplification program for all fragments, except the marker D3S666,
consisted of denaturation at 95C for 15 min, then 40 cycles of denaturation at
95C for 1 min, annealing at 55C for 1 min, and extension at 72C for 1 min.
The program was finished by 72C incubation for 7 min. Annealing tem-
perature for fragment D3S666 was 58C. PCR products of the VHL gene were
purified with Montage PCR Centrifugal Filter Devices (Millipore, USA) and
sequenced using a Big Dye Terminator Sequencing kit (PE/Applied Bio-
systems, USA). Samples were then run on an automated sequencer (ABI
Prism 310; PE/Applied Biosystems) at a constant voltage of 11.3 kV for
20 min. PCR products of STR markers were mixed with a size marker and run
on an automated sequencer (ABI Prism 310; PE/Applied Biosystems) at a
constant voltage of 15 kV for 28 min.
Genomic DNA was isolated from three 5 mM thick paraffin sections of each
renal carcinoma sample using the Ex-Wax DNA Extraction Kit (Chemicon
International, USA) according to the manufacturer’s instructions. Bidirec-
tional sequencing of PCR products was performed using an ABI Prism
BigDye terminators v3.1 cycle sequencing kit (Applied Biosystems), and
sequences were run on an Applied Biosystems 3130 Genetic Analyzer and
compared with the reference sequence CCDS 2597.1. The PCR amplicon
carrying the mutation was subcloned into a pGEM-T Easy vector (Promega,
USA), transformed in competent DH5a cells and plated onto LB agar with
ampicillin and X-gal selection. Then, 12 distinct blank (white) colonies were
chosen, plasmid DNA was extracted and submitted for amplification and
sequencing of VHL exon 3 as described above.
Methylation-specific multiplex ligation-dependent probe amplification
(MS-MLPA) and CpG methylation analysis
Microdissection of tissues from the five FFPE kidney tumours was performed
manually. Genomic DNA extracted from the three samples was subjected to
MS-MLPA using ME001-0808-C1 and ME002-0809-B1 probemixes (MRC-
Holland, The Netherlands) with 20–100 ng of DNA per sample. The standard
MS-MLPA-protocol was employed.20 Both probemixes contained one spe-
cific MLPA probe for the exon 1 of VHL gene that has a recognition site for a
CpG methylation-sensitive endonuclease HhaI. The MS-MLPA product
fragments were analysed by an ABI model 3130 capillary sequencer (Applied
Biosystems, The Netherlands) using Genescan-ROX 500 size standards. As
the same probemixes are intended to detect both copy number and methyl-
ation changes of the target genes simultaneously, both methylation and copy
number status was analysed using Coffalyser software (MRC-Holland). The
data were first normalised by dividing the peak area of a single probe by a
cumulative peak area of all control probes (not degraded by HhaI). Then, the
normalised peaks from the HhaI digestion reaction were compared to the
normalised peaks from the undigested control reaction. Final methylation
value for each sample was obtained by subtracting the background methyl-
ation values of the control samples (male and female DNA samples; Prom-
ega). The following criteria were used for determining the methylation status:
0.00–0.25 (absent), 0.25–0.50 (mild), 0.50–0.75 (moderate), and >0.75
(extensive methylation). For copy number analysis the following cut-off
values were used: <0.7 and >1.3 gain. One DNA sample (labelled 8656)
was excluded from the analysis due to the low amount of DNA and for
another sample (labelled 10684) we were able to include only results usingME002-0809-B1 probemix as no DNA was available for the further analysis
using the ME-001-0808 mix.
TCEB1 mutation analysis
TCEB1 gene Y79 and A100 hotspots were analysed by Sanger sequencing
(Cases 1–5). PCR products were purified using Agencourt AMPure XP
magnetic beads (Beckman Coulter, USA) and labelled with Big Dye
Terminator v3.1 (Applied Biosystems, Italy). Agencourt CleanSEQ magnetic
beads (Beckman Coulter) were used for post-labelling DNA fragment puri-
fication, and sequence analysis was performed on an Applied Biosystems
3130xl Genetic Analyzer.
RESULTS
Clinical and pathological findings
The patients were nine males and five females, with a mean
age of 61 years (range 46–77 years). All tumours were well
circumscribed, with a mean diameter of 2.4 cm (range
1.2–4.0 cm). All cases were pT1a. The clinical and path-
ological data of the cases are summarised in Table 1.
Macroscopically, one tumour (Case 5) exhibited a pre-
dominantly solid and greyish appearance, while the other
13 showed a variable cystic and solid morphology (Fig. 1
and 2). No necrotic foci were seen. One tumour (Case 3)
was yellow with a solid-microcystic appearance reminis-
cent of a conventional clear cell RCC. Microscopically,
tumours showed encapsulation with differing architectural
patterns as summarised in Table 2. The papillary pattern
was unique in that it occurred secondarily within enlarged
tubules and cysts. Other architectural patterns were also
present. These consisted of branching tubules similar to
benign prostatic acini, and tubulo-glandular structures of
variable sizes and shape, sometimes with ill-formed lumina
imparting a solid appearance. Variable sized cysts were also
seen, predominantly at the periphery of the tumour. All
tumour cells had clear cytoplasm with nuclei aligned
circumferentially, resembling secretory endometrium
(Fig. 2E–H). The nuclei of all cases were predominantly
low grade (ISUP nucleolar grade 1 or 2) (Fig. 3A–D). The
stroma was hyalinised although occasionally fibroleio-
myomatous areas were also seen. Necrosis, mitotic activity,
vascular invasion, or sarcomatoid change was not observed
in any case.
Immunohistochemical findings
Immunohistochemical findings are summarised in Table 3
and Fig. 3. Half of the cases were positive for CD10,
ranging from 5% to 70% of neoplastic cells, and there was
diffuse positivity for CK7 in 70–100% of cells. CK AE1-
AE3 expression was seen in 100% of the neoplastic cells
in all cases. SLC2A1 (GLUT1) and CAIX displayed vari-
able intensity of expression in all, and in all but one case,
respectively (one case not available for CAIX). Cytokeratin
34bE12 and CK14 showed an equivalent pattern of staining
as they were expressed in the same 12 cases (12/14, 86%);
Cases 3 and 6 were completely negative for both markers
(Fig. 3E–H). CK1 and CK10 were constantly negative
while CK5 showed positivity in four cases (percentages
variable from 10 to 80%). Alpha-methylacyl-CoA racemase
(P504S), HMB-45, cathepsin k, and oestrogen and proges-
terone receptors were constantly negative. S100A1 was
expressed in nine of 13 cases (one case was not available),
while parvalbumin showed weak immunoreactivity in 20%
Table 1 Main clinical and pathological data of the 14 cases of clear cell papillary renal cell carcinoma
Case no. Sex Age Surgery Diameter, cm Necrosis Grade Follow-up, months pT
1 F 59 Left nephrectomy 2 Absent 2 48 pT1a
2 M 70 Enucleation 1.5 Absent 2 71 pT1a
3 M 55 Enucleation 4 Absent 1 83 pT1a
4 M 55 Right nephrectomy 3 Absent 2 122 pT1a
5 F 61 Enucleation 3.4 Absent 2 141 pT1a
6 F 64 Enucleation 1.6 Absent 1 54 pT1a
7 M 77 Enucleation 3 Absent 1 64 pT1a
8 M 72 Enucleation 1.8 Absent 1 106 pT1a
9 M 50 Enucleation 1.6 Absent 2 129 pT1a
10 M 61 Enucleation 3.8 Absent 1 137 pT1a
11 F 64 Enucleation 3.2 Absent 2 75 pT1a
12 M 68 Enucleation 2.1 Absent 2 24 pT1a
13 F 51 Enucleation 1.2 Absent 2 38 pT1a
14 M 46 Enucleation 1.5 Absent 2 27 pT1a
Fig. 1 Macroscopically, (A) Case 4 showed cystic and focally solid morphology, whereas (B) Case 5 exhibited a predominantly solid and white-mahogany brown
appearance.
34bE12 FOR CLEAR CELL PAPILLARY RENAL CARCINOMA 13and 10% of the neoplasic cells in Cases 10 and 13,
respectively. The stroma of the tumours showed focal
positivity for alpha-smooth muscle actin in 12 of 14 cases,
whereas there was complete negativity in the remaining two
tumours. Only two of 150 clear cell RCC cases (1%) of the
TMAs stained weakly positive for 34bE12 and CK14. We
previously stained the same 150 conventional clear cell
RCCs for CK7 and found it positive in 36 of 150 (24%) of
the cases.
Western blot results
Two cases (Cases 2 and 4) revealed the appropriate positive
band referring to CK14, respectively positive at immuno-
histochemistry in 60% and 40% of neoplastic cells. One case
(Case 3) did not express the protein band, and was negative at
immunohistochemistry. One case (Case 5) did not show ev-
idence of the protein band but expression was observed in up
to 40% of neoplastic cells at immunohistochemistry. The
remaining two cases showed faint protein bands (Cases 10
and 14). Eight of 10 conventional clear cell RCCs were
negative and two tumours showed a weak positive band.
aCGH results
We did not observe any gene copy number alterations in four
of five cases analysed. DNA copy number changes were
found in one tumour (Case 3) that showed deletions in
chromosomes 3 (3p26.3q23, 3q25.1q25.2 and 3q25.32q26.2)
and 6 (6q15q27) (Fig. 4, Table 4).FISH findings
We analysed five cases by FISH.
Locus specific sub-telomeric 3p probe
Single, double and three or more fluorescent signals,
respectively, were shown in neoplastic epithelial nuclei as
follows: Case 1, 33%, 58% and 9%; Case 2, 34%, 61% and
5%; Case 3, 31%, 65% and 3%; Case 4, 35%, 59% and 6%;
Case 5, 39%, 55% and 6%.
Centromeric chromosome 3 probe
Single, double and three or more fluorescent signals,
respectively, were shown in neoplastic epithelial nuclei as
follows: Case 1, 29%, 61% and 10%; Case 2, 35%, 62% and
3%; Case 3, 11%, 69% and 20%; Case 4, 44%, 53% and 9%;
Case 5, 35%, 60% and 5%. The value of the ratio of the
normal renal parenchyma + 3SD set to 1.03 + 3SD
0.05 = 1.19. The ratio was 1.02 in Case 1 (not deleted), 1.09
in Case 2 (not deleted), 1.18 in Case 3 (not deleted), 1.12 in
Case 4 (not deleted) and 1.02 in Case 5 (not deleted). All five
tumours showed no gains of chromosomes 7 and 17 with
single signals ranging from 33 to 43, double signals from 53
to 61 and more than two signals from 5 to 15, respectively.
VHL gene mutation
No mutation of coding sequence of the VHL gene was found
in epithelial neoplastic components in four of five cases,
Fig. 2 The tumours show a variable cystic and solid morphology (A, Case 2; B, Case 3; C, Case 4; D, Case 5). They exhibit different architectural patterns, including
tubulo-glandular structures intermixed with areas composed of branching tubules (E, Case 2; F, Case 3), cystic and papillary structures (G, Case 4) and homogeneous
tubulo-glandular structures (H, Case 5).
14 MARTIGNONI et al. Pathology (2017), 49(1), Januarywhereas one tumour (Case 3) showed a deletion in exon 1
(c.213del) (Table 4).
MLPA findings on methylation and copy number status
of VHL
MS-MLPA analysis of FFPE tissue DNA samples showed
absent or mild methylation of VHL gene; the copy number of
VHL gene was stable in all five analysed cases (Table 5).
TCEB1 gene mutation
No mutation of coding sequence of the TCEB1 gene was
found in any tumour.
DISCUSSION
In this study we have demonstrated that: (1) the distinction
between CCPRCC and low malignant potential multicysticRCC or conventional clear cell RCC, on the basis of
morphological features, can be difficult; (2) the immunohis-
tochemical expression of CK7 is necessary, but not sufficient
to identify CCPRCC; (3) the immunoreactivity for 34bE12,
in part due to the presence of CK14 in the neoplastic cells,
can be extremely useful for identifying this tumour; (4) FISH
can verify the presence of gains of chromosome 7 and 17 to
differentiate CCPRCC from papillary RCC with clear cell
changes, but it is not discriminatory when evaluating 3p
status in differentiating this tumour from low malignant po-
tential multicystic RCC or conventional clear cell RCC; (5)
mutational analysis is the single most reliable method to
differentiate rare CK7 positive conventional clear cell RCCs
from CCPRCC; (6) the characteristic immunoprofile,
including 34bE12 expression, and genomic signature,
absence of 3p abnormalities, are observed in the entire
morphological spectrum of CCPRCCs; (7) CCPRCC lacks
Table 2 Frequency of different architectural pattern in the five cases
selected for molecular analysis
Case no. Architectural patterns (%)
Papillary Branching tubules Tubulo-glandular Cystic
1 60 0 10 30
2 30 50 10 10
3 20 30 45 5
4 40 10 0 50
5 10 0 90 0
34bE12 FOR CLEAR CELL PAPILLARY RENAL CARCINOMA 15TCEB1 mutation. Although CCPRCC was initially described
as a multicystic neoplasm with a prominent papillary archi-
tecture and composed of cells with clear cytoplasm, subse-
quent series of this tumour have shown a broader spectrum of
morphological features. Aydin et al. and Williamson et al.Fig. 3 The branching tubules display similar features to benign prostatic acini (A, Ca
circumferentially, resembling secretory endometrium. The nuclei are predominantly low
G, Case 4; H, Case 5); 34bE12 positivity (I, Case 2) and negativity (J, Case 3); immuhighlighted that the papillary component is present only in
81% and 65% of cases, emphasising the branched tubular
pattern, rather than the papillary pattern, as a distinctive
morphological characteristic. This latter aspect, however, was
often missing in tumours with a prominent cystic compo-
nent.3,21 These data underscore the difficulties that may be
encountered in distinguishing this tumour from papillary
RCC with prominent clearing of cytoplasm,21 as well as low
malignant potential multicystic clear cell and conventional
clear cell RCC. Such difficulty has been clearly demonstrated
by Williamson et al. who reported that 14 CCPRCCs were
identified from 469 RCC resections performed from 2004 to
2006 and that the majority of these tumours were originally
diagnosed as clear cell RCC.9 Their work reinforced the
notion that there can be substantial morphological overlap
between CCPRCC and conventional clear cell RCCs as only
a single tumour with an original diagnosis of papillary RCCse 2; B, Case 3); all tumour cells show clear cytoplasm with nuclei aligned
-grade (C, Case 4; D, Case 5). Diffuse expression of CK7 (E, Case 2; F, Case 3;
noexpression of CK14 (K, Case 4; L, Case 5).
Table 3 Immunohistochemical findings of the 14 cases of clear cell papillary renal cell carcinoma
Case no. CK7 CD10 AMACR CAIX GLUT-1 PV S100A1 HMB45 CAT K SMA DES AE1-AE3 34bE12 CK14 CK5 CK1 CK10 ER PR
1 80 Neg Neg 50 50 Neg Neg Neg Neg 60 Neg 80 60 30 Neg Neg Neg NA NA
2 100 10 Neg 60 30 Neg Neg Neg NA 70 Neg 80 100 60 80 Neg Neg Neg Neg
3 70 70 Neg 10 80 Neg 10 Neg Neg 10 Neg 70 Neg Neg Neg Neg Neg Neg Neg
4 80 Neg Neg 90 90 Neg 30 NA Neg 30 Neg 90 20 40 Neg Neg Neg Neg Neg
5 90 40 Neg 40 40 Neg 50 Neg Neg 60 Neg 60 80 40 30 Neg Neg Neg Neg
6 80 Neg Neg 30 50 Neg Neg Neg NA 10 Neg 70 Neg Neg Neg Neg Neg Neg Neg
7 100 Neg Neg 50 70 NA NA Neg NA 30 Neg 80 80 60 Neg Neg Neg Neg Neg
8 100 Neg Neg NA NA Neg 60 Neg Neg Neg Neg 80 80 80 Neg Neg Neg Neg Neg
9 90 Neg Neg 30 70 Neg Neg Neg Neg Neg Neg 80 30 30 Neg Neg Neg Neg Neg
10 90 Neg Neg 60 90 20 10 Neg Neg 30 Neg 70 60 20 Neg Neg Neg Neg Neg
11 90 10 Neg 90 70 Neg 70 Neg Neg 70 Neg 100 90 60 10 Neg Neg Neg Neg
12 70 40 Neg 90 60 Neg 60 Neg Neg 80 Neg 80 80 70 Neg Neg Neg NA NA
13 80 50 Neg 90 60 10 90 NA Neg 40 Neg 70 80 50 10 Neg Neg Neg Neg
14 70 10 Neg 90 50 Neg 80 NA Neg 70 Neg 90 30 20 Neg Neg Neg NA NA
AMACR, alpha-methylacyl-CoA racemase (P504S); CAIX, carbonic anhydrase IX; CAT K, cathepsin K; CK, cytokeratin; DES, desmin; ER, oestrogen receptor;
NA, not applicable; PR, progesteron receptor; PV, parvalbumin; SMA, smooth mucle actin.
Results of desmin and SMA are referred to the intratumoural stroma.
Fig. 4 Array CGH results in five cases initially diagnosed as clear cell papillary renal cell carcinoma with microscopic features representative of the morphological
spectrum described so far in the literature. DNA copy number changes were found in only one tumour (Case 3) that presented deletions in chromosome 3 (3p26.3q23,
3q25.1q25.2 and 3q25.32q26.2) and 6 (6q15q27).
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as multilocular cystic RCCs. Recently, CCPRCC-like tu-
mours have been described in patients with or without von
Hippel–Lindau disease unrelated to sporadic CCPRCC,
highlighting once again the difficulties that one might
encounter in distinguishing CCPRCC from conventional
clear cell RCC.10 In support of the diagnostic difficulties
mentioned above, one of the tumours (Case 3) that we
selected as CCPRCC, based on morphological and immu-
nophenotypical features (diffuse papillary architecture with a
characteristic arrangement of the nuclei, as well as the pres-
ence of branched tubules and CK7 positivity), proved to be a
conventional clear cell RCC with alterations of 3p identified
by aCGH and VHL mutation. This tumour showed a strong
and diffuse immunoreactivity for CK7 (70% of the neoplastic
cells), a marker currently considered as extremely useful for
differentiating CCPRCC from clear cell RCC.2,5 Although
the majority of clear cell RCCs lack CK7 immunoexpression,
some cases have been reported to be positive for this marker.
We performed a literature search encompassing a total of 391
cases of clear cell RCC and found that 44 (12%) expressed
CK7.22–25 Moreover, in our hands we have demonstrated this
immunoreactivity in 24% of clear cell RCC. Finally,
Williamson and Cheng have reported a group of clear cellRCCs with borderline features of clear cell RCC, including
cytokeratin 7 expression in 18 of 22 and 34bE12 in seven of
21.26
As we demonstrated here, this might lead to misdiagnosis,
even in the presence of morphological features typical of
CCPRCC. 34bE12 is an antibody that recognises different
high molecular weight cytokeratins including CK1, 5, 10 and
14; interestingly, we found 34bE12 to be positive in all but
two cases (12/14), one of these being the CK7 positive clear
cell RCC case. Of note, only in 2011 was it initially reported
that 34bE12 immunoexpression was observed in CCPRCC,
and only recently Brimo et al.27 and Aron et al.12 reported
additional CCPRCC with such positivity (Table 6). Aron
et al. showed 41 of 42 cases with immunoexpression of
34bE12.12 Rohan et al. showed seven of nine (78%) of their
CCPRCC cases to be positive for this marker; on the other
hand, 34bE12 immunostain was not detected in any of their
clear cell RCC tested (0/11).5 In our control group accounting
for 150 clear cell RCCs, only two cases (1%) showed posi-
tivity for this marker. In order to better understand which
specific cytokeratin is most responsible for the observed
34bE12 positivity in CCPRCC, we evaluated the immu-
noexpression of CK1, CK5, CK10 and CK14 separately. We
found that, among these molecules, CK14 followed by CK5
Table 4 Synthesis of molecular findings of the five cases initially diagnosed as clear cell papillary renal cell carcinoma with microscopic features representative of
the morphological spectrum described so far in the literature
Case no. aCGH Chr 3p Ratio 3/3p Chr 7 Chr 17 VHL status
1 Normal status Disomy 1.02 Disomy Disomy WT
2 Normal status Disomy 1.09 Disomy Disomy WT
3 3p26.3q23, 3q25.1q25.2, 3q25.32q26.2, 6q15q27 Disomy 1.18 Disomy Disomy Deletion in exon 1 (c.213del)
4 Normal status Disomy 1.12 Disomy Disomy WT
5 Normal status Disomy 1.02 Disomy Disomy WT
Findings from three different molecular methods investigating chromosomal imbalances: array comparative genomic hybridisation (aCGH), chromosomes 3p, 7 and
17 status (fluorescence in situ hybridisation; FISH) and VHL status (gene sequencing).
Table 5 Methylation status and gene copy number of the five cases initially diagnosed as clear cell papillary renal cell carcinoma with microscopic features
representative of the morphological spectrum described so far in the literature










1 0.00 0.00 1.16 1.05
2 0.11 0.28 1.14 1.08
3 0.00 0.00 0.75 0.89
4 0.00 0.00 0.99 1.03
5 0.00 0.08 1.01 0.92







Tickoo et al. 2006 15 IHC not performed
Gobbo et al. 2008 5 CK34bE12 not performed
Mai et al. 2008 10 CK34bE12 not performed
Lopez et al. 2010 12 0/12
Aydin et al. 2010 33 CK34bE12 not performed
Adam et al. 2011 24 CK34bE12 not performed
Wolfe et al. 2011 1 CK34bE12 not performed
Rohan et al. 2011 9 7/9 (78%)
Park et al. 2012 15 CK34bE12 not performed
Bhatnagar et al. 2012 14 CK34bE12 not performed
Cui et al. 2013 20 CK34bE12 not performed
Williamson et al. 2013 34 CK34bE12 not performed
Shi et al. 2013 11 CK34bE12 not performed
Fisher et al. 2014 17 CK34bE12 not performed
Rao et al. 2014 3 CK34bE12 not performed
Zhou et al. 2014 12 CK34bE12 not performed
Alexiev et al. 2014 5 5/5 (100%)
Alexiev et al. 2014 28 28/28 (100%)
Leroy et al. 2014 42 CK34bE12 not performed
Lawrie et al. 2014 17 CK34bE12 not performed
Deml et al. 2015 27 CK34bE12 not performed
Yan et al. 2015 6 CK34bE12 not performed
Diolombi et al. 2015 58 CK34bE12 not performed
Brimo et al. 2015 9 9/9 (100%)
Aron et al. 2015 45 43/45 (96%)
Martignoni et al. This study 14 12/13 (92%)
IHC, immunohistochemistry.
34bE12 FOR CLEAR CELL PAPILLARY RENAL CARCINOMA 17are the most highly immunoexpressed high molecular weight
cytokeratins in CCPRCC; these results are more likely to be
verified by western blot analysis rather than immunohisto-
chemical analysis. We also evaluated the expression of CK14in TMAs containing 150 cases of conventional clear cell
RCC and only the two cases positive for 34bE12 expressed
CK14. Therefore, we suggest that applying 34bE12 to the
immunohistochemical panel for diagnosing CCPRCC might
be useful for distinguishing the latter from conventional clear
cell RCC. Although FISH analysis is an extremely valuable
aid for discriminating the different RCC histotypes, this is not
always the case for CCPRCC versus clear cell RCC.5,15 In
fact, in the tumour that we reclassified as clear cell RCC, only
aCGH and gene sequencing allowed us to detect chromo-
somal imbalances and VHL alteration. However, FISH
analysis remains a precise tool for detection of chromosome 7
and 17 gains, thus permitting the distinction between
CCPRCC and papillary RCC. Interestingly, after the reclas-
sification of our Case 3 as clear cell RCC, we went back to the
diagnostic report of this tumour where it was described as a
solid and microcystic yellowish lesion typical of clear cell
RCC, which was in contrast to the gross characteristics of the
other tumours in our series. Finally, Hakimi et al.14 have
recently reported that at least part of the so called RCC
with angioleiomyoma-like stroma28,29 which shows over-
lapping morphological and immunophenotypical features
with CCPRCC, carries mutations in TCEB1, a gene that
contributes to the VHL complex to ubiquitinate hypoxia-
inducible factor. We confirmed their data regarding the
absence of TCEB1 mutations in CCPRCC. Distinguishing
CCPRCC from clear cell RCC is important, since the
former has yet to be reported as having a malignant po-
tential in cases with extensive genetic studies. As we noted
above, despite having often distinctive morphological and
immunohistochemical characteristics, these two entities can
show overlapping features in few cases, resulting in diag-
nostic errors. In this study we have demonstrated that CK7
positivity and FISH evaluation for 3p deletion, although
18 MARTIGNONI et al. Pathology (2017), 49(1), Januaryfrequently useful, might not be sufficient for distinguishing
CCPRCC from conventional clear cell RCC in a minority
cohort. In view of this we propose the use of 34bE12 to
improve diagnostic accuracy in this differential diagnosis.
and VHL mutation analysis should be considered the gold
standard to evaluate cases characterised by chromosome 3p
deletion associated with both CK7 and 34bE12 expression.
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